Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0XLSWN
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
SC-006
|
|||||
| Synonyms |
SC 006; SC-006; SC006
Click to Show/Hide
|
|||||
| Organization |
AbbVie, Inc.
|
|||||
| Drug Status |
Phase 1 (Terminated)
|
|||||
| Indication |
In total 1 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
E3 ubiquitin-protein ligase RNF43 (RNF43)
|
Antigen Info | ||||
| Payload Name |
SC-DR003
|
Payload Info | ||||
| Therapeutic Target |
Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
| Combination Type |
tesirine
|
|||||
| TTD ID | ||||||
| ChEBI ID | ||||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
0.00%
|
|||
| Patients Enrolled |
Patients with advanced metastatic or unresectable colorectal cancer.
|
||||
| Administration Dosage |
SC-006-monotherapy, 2 to 12 ug/kg IV every 3 weeks.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT03035279 | Clinical Status | Phase 1 | ||
| Clinical Description | An open label phase 1 study of SC-006 as a single agent and in combination with ABBV-181 in subjects with advanced colorectal cancer. | ||||
References